Adverum reviews recent business progress and unveils its 2020 outlook
Category: #health  By Mateen Dalal  Date: 2020-01-14
  • share
  • Twitter
  • Facebook
  • LinkedIn

Adverum reviews recent business progress and unveils its 2020 outlook

Adverum Biotechnologies, a California based biotech company, has reportedly announced that it has examined its recent business & development progress. The company has also unveiled its outlook for 2020.

Leone Patterson, president and chief executive officer, Adverum Biotechnologies, stated that the company made a considerable progress back in 2019, by advancing its gene therapy candidate namely ADVM-022, in OPTIC phase 1 with dose ranging clinical stage trial in patients along with wet AMD.

Patients having wet AMD require regular ocular anti-VEGF, that stands for Vascular Endothelial Growth Factor, injections in order to retain their vision. Additional data was presented regarding the first group of patients in OPTIC, demonstrating rescue injections that are zero anti-VEGF and are required following a single intravitreal injection of therapy candidate ADVM-022 with a median follow up of around 44 weeks, the treatment of ADVM-022 was concluded to be well-tolerated as we as safe. Additional data concerning all four groups of patients in OPTIC will be presented this year.

Patterson further added that the company plans to present an IND for ADVM-022 in a second indication along with diabetic retinopathy, and also start enrolling patients for the new clinical trial. It is also believed that ADVM-022 is likely an ideal treatment for patients having wet AMD and also for patients detected with diabetic retinopathy.

On January 11, 2020, at the Atlantic Coast Retina Club, Adverum presented a median follow up data of around 44 weeks. The data showed that patients in the first group of OPTIC accomplished improvements in retinal anatomy and vision maintenance with no anti-VEGF rescue injections needed for any patient.

About Adverum Biotechnologies:

Adverum Biotechnologies is publicly traded gene therapy company that targets unmet rare and ocular diseases medical needs. Adverum is assessing its new gene therapy candidate, namely ADVM-022, for treating patients with wet AMD.

Source credit: http://investors.adverum.com/news-releases/news-release-details/adverum-biotechnologies-reports-continued-momentum-optic-trial

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

AstraZeneca to present results of Farxiga’s DAPA-CKD trial at ESC 2020
AstraZeneca to present results of Farxiga’s DAPA-CKD trial at ESC 2020
By Mateen Dalal

According to reliable sources, British-Swedish multinational pharmaceutical company AstraZeneca plc will present the much awaited results of the Phase III DAPA-CKD trial of Farxiga in CKD (chronic kidney disease) at ESC Congress 2020. Sources with r...

FDA grants Emergency Use Authorization to Abbott’s COVID-19 antigen
FDA grants Emergency Use Authorization to Abbott’s COVID-19 antigen
By Mateen Dalal

Abbott Laboratories, a U.S.-based medical devices and healthcare firm, has reportedly received the Emergency Use Authorization (EUA) from the U.S. FDA (Food and Drug Administration) for the detecting COVID-19 virus with its portable antigen test Bina...

Hyundai Wia Corp. signs gun parts export contract with BAE Systems
Hyundai Wia Corp. signs gun parts export contract with BAE Systems
By Mateen Dalal

Hyundai Wia Corp., a South Korea-based defense firm, has reportedly signed gun parts export contract with BAE Systems plc of worth USD 100 million via a pre-value accumulation system. As per the agreement, Hyundai Wia will supply over 106 types of gu...